Navigating Market Volatility: Three ASX Penny Stocks With Potential for February 2026

The Australian sharemarket is set for a shaky opening this week, with futures pointing to a 0.8% decline. The shadow of a potential Reserve Bank rate hike and ongoing global economic uncertainty has prompted a flight to caution among investors. In such an environment, the search for value often leads to the smaller end of the market. While penny stocks carry inherent risk, a focus on fundamental strength can uncover companies poised to weather the storm or capitalise on niche growth. We analyse three ASX-listed penny stocks that demonstrate robust balance sheets alongside strategic initiatives that could drive long-term value.

Central Petroleum Ltd (ASX:CTP)
Market Cap: A$55.54M | Simply Wall St Financial Health Rating: ★★★★★☆
This Australian hydrocarbon developer and producer, with revenue of A$43.63 million, presents a picture of improving financial health. A strengthened balance sheet shows cash reserves outweighing total debt, and interest payments are comfortably covered by earnings. Although recent earnings have been negative, analysts forecast annual growth of over 40%. A significant reduction in its debt-to-equity ratio over five years to 57.2% underscores this turnaround. The recent appointment of experienced upstream operator Joel Riddle to the board is seen as a strategic move to guide its growth initiatives in the energy sector.

Michael Hill International Ltd (ASX:MHJ)
Market Cap: A$153.94M | Simply Wall St Financial Health Rating: ★★★★☆☆
The well-known jewellery retailer, generating A$645.31 million in revenue across ANZ and Canada, has recently returned to profitability. Its liquidity position is strong, with short-term assets covering all liabilities. However, challenges remain: return on equity is low at 1.2%, and while operating cash flow covers debt, earnings cover interest payments by a thinner margin of 2.7 times. The company trades below its estimated fair value. A key development is the upcoming appointment of Elodie Guillaumond as CFO in February 2026, bringing seasoned financial leadership to navigate the competitive retail landscape.

SomnoMed Ltd (ASX:SOM)
Market Cap: A$146.36M | Simply Wall St Financial Health Rating: ★★★★★★
Specialising in oral devices for sleep disorders, SomnoMed boasts the highest financial health rating of the trio. With revenue of A$111.49 million, it holds more cash than debt and has a cash runway exceeding three years, providing a significant buffer despite not yet being profitable. Its expansion of managed care infrastructure in the critical U.S. market aims to improve patient access to its therapies. Trading below fair value with solid liquidity, the stock is flagged by analysts for potential price growth, though its negative return on equity and widening losses over five years are noted headwinds.

This analysis is based on historical data and analyst forecasts using an unbiased methodology. It is not intended as financial advice and does not constitute a recommendation to buy or sell any security. It does not consider your individual objectives or financial situation. Our commentary is long-term focused and driven by fundamental data, and may not incorporate the latest company announcements.

Simply Wall St has no position in the stocks mentioned.

Market Voices: Investor Reactions

Priya Sharma, Portfolio Manager (Sydney): "In a tightening cycle, liquidity and debt coverage are paramount. Central Petroleum's turnaround on leverage and SomnoMed's extensive cash runway make them interesting case studies for defensive positioning within the speculative end of the market."

David Chen, Retail Investor (Melbourne): "Michael Hill feels like a turnaround story that's still mid-turn. The new CFO could be the catalyst it needs, but that ROE is a major red flag for me. I'd need to see a clearer path to efficiency improvements."

Marcus O'Sullivan, Independent Analyst (Perth): "This is just hunting for needles in a haystack. The entire premise is flawed—throwing darts at micro-caps when the RBA is about to hike? This is how retail investors get slaughtered. SomnoMed burns cash, Michael Hill struggles for relevance, and an oil & gas junior? Seriously?"

Eleanor Green, Private Wealth Advisor (Brisbane): "For a very small, high-risk sleeve of a portfolio, the fundamental screening here is sensible. It's not about picking winners, but avoiding the obvious losers. These three at least show some financial discipline, which is the first filter in this space."

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]